DeepGI
Category: AI in Healthcare
AI-powered real-time gastrointestinal cancer detection system for endoscopic procedures DeepGI was founded in 2022. The company is led by Prof. Dr. Rungsun Rerknimitr. Based in Bangkok, Thailand. Team size: 10-50. Total funding raised: $570K. Latest round: Government Grant. Key investors include Thailand Board of Investment, Chulalongkorn University, Natural Sciences and Engineering Research Council of Canada (NSERC).
- Founded
- 2022
- Headquarters
- Bangkok, Thailand
- Team size
- 10-50
- Total funding
- $570K
Value proposition
Real-time AI assistance achieving 97% accuracy in detecting gastrointestinal cancers and precancerous lesions, trained on localized Thai medical data
Products and solutions
DeepGI for Colorectal Cancer Detection, DeepGI for Gastric Cancer Detection, DeepGI for Bile Duct Cancer Detection, Real-time polyp detection and characterization, DeepGI CADx (Computer-Aided Diagnosis) for lesion classification
Unique value
First AI system worldwide to simultaneously detect colorectal, gastric, and bile duct cancers in real-time; trained specifically on Thai medical data for superior local accuracy; vendor-agnostic compatibility
Target customer
Hospitals, diagnostic centers, and gastroenterologists performing endoscopic procedures
Industries served
Healthcare, Medical Diagnostics, Gastroenterology
Technology advantage
Advanced deep learning algorithms with 97% detection accuracy, real-time processing capabilities, extensive training on hundreds of thousands of endoscopic images, vendor-agnostic deployment
How they differentiate
Multi-organ detection capability (colorectal, gastric, bile duct), localized training on Thai medical data, real-time processing with 97% accuracy, vendor-agnostic compatibility
Main competitors
Iterative Scopes, Medtronic GI Genius, Docbot
Key partnerships
Chulalongkorn University Faculty of Medicine, Chulalongkorn University Faculty of Engineering, King Chulalongkorn Memorial Hospital, Thailand Board of Investment, ESM Solutions Co., Ltd.
Notable customers
King Chulalongkorn Memorial Hospital, 35 local screening facilities across Thailand (government-based endoscopy centers)
Major milestones
Thai FDA approval obtained for colorectal screening, 97% detection accuracy achieved, Phase 2 expansion to gastric and bile duct cancers completed June 2025, 35-unit nationwide pilot deployment active across Thailand, Shortlisted for THE Awards Asia 2026, Phase 3 CADx (computer-aided diagnosis) development launched, Presented at IDEN 2025 and ENDO 2024 conferences, 86.56% accuracy in detecting gastric intestinal metaplasia validated
Growth metrics
35 units deployed across local screening facilities nationwide, 97% detection accuracy for colorectal, 86.56% accuracy for gastric intestinal metaplasia, Thai FDA approval obtained for colorectal screening, Phase 3 CADx development underway
Market positioning
Leading AI gastrointestinal screening solution in Thailand, transitioning from academic research to commercial deployment
Geographic focus
Thailand with potential expansion to Southeast Asian markets
Patents and IP
Patent application in process for polyp detection technology
About Prof. Dr. Rungsun Rerknimitr
Professor of Medicine at Chulalongkorn University, Assistant to the President for Innovation, GI endoscopy specialist with expertise in advanced therapeutic GI endoscopy and medical innovation
Official website: https://deepgi.co/